CD274 and neoplasm: This benefit was greatest in patients with stage IIIA disease (HR for disease progression, recurrence, or death of 0.54), a tumor PD-L1 expression of ≥ 1% (MPR of 44.9%, PCR of 32.6%), and in patients with non-squamous histology.